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Research Article  
One-sentence summary: Mice lacking the HSN2 form of the WNK1 kinase are protected from neuropathic pain 
due to nerve injury. 
 
Overline (20 characters max): Pain  
 
Rotator title: “WNK”ing out pain 
Rotator teaser: Blocking the HSN2 form of the kinase WNK1 reduces neuropathic pain 
 
Editor’s Summary: 
“WNK”ing out pain  
 
Mutations in the HSN2 exon present in the nervous system specific isoform of the serine-threonine kinase WNK1 
cause a Mendelian form of congenital insensitivity to pain, termed hereditary sensory and autonomic neuropathy 
type IIA (HSANII). HSANII affects the peripheral and spinal nerves and results in loss of touch, temperature, and 
pain sensation. Kahle et al. generated transgenic mice specifically lacking this alternatively-spliced variant of 
WNK1, which is highly expressed in the spinal cord’s dorsal horn, the gateway for pain processing from the 
periphery to the brainstem. These mice exhibited no gross neurological defects and did not exhibit symptoms of 
HSANII, likely because mutations in HSANII patients generate a truncated form of the kinase retaining an intact 
catalytic domain. The HSN2-deficient mice were protected from pain hypersensitivity in a model of neuropathic 
pain resulting from peripheral nerve injury, but not in an inflammatory pain model. Mechanistically, HSN2-deficient 
mice had less maladaptive inhibitory phosphorylation of the K+-Cl- cotransporter KCC2 in spinal cord, thereby 
resetting of the inhibitory response to GABA. Thus, by alleviating GABA “disinhibition”, a known major 
contributor to neuropathic pain, drugs that inhibit HSN2 might be able to reduce injury-induced neuropathic pain, a 
current unmet need for many patients. 
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Abstract 
HSN2 is a nervous system-predominant exon of of the WNK1 kinase (HSN2-containing 
splice variant referred to as “WNK1/HSN2”) and is mutated in an autosomal recessive, inherited 
form of congenital pain insensitivity. We created a knockout mouse specifically lacking the 
HSN2 exon of WNK1. Although these mice had normal spinal neuron and peripheral sensory 
neuron morphology and distribution, the mice were less susceptible to hypersensitivity to cold 
and mechanical stimuli after peripheral nerve injury. In contrast, thermal and mechanical 
nociceptive responses were similar to control mice in an inflammation-induced pain model. In 
the nerve injury model of neuropathic pain, WNK1/HSN2 contributed to a maladaptive decrease 
in the activity of the K+-Cl- cotransporter KCC2 by increasing its inhibitory phosphorylation at 
Thr906 and Thr1007, resulting in an associated  loss of GABA-mediated inhibition of spinal pain-
transmitting nerves. Electrophysiological analysis showed that WNK1/HSN2 shifted the 
concentration of Cl- such that GABA signaling resulted in depolarization (increased neuronal 
activity) rather than hyperpolarization (decreased neuronal activity) in mouse spinal nerves. 
Consistent with the results in the WNK1/HSN2-deficient mice, pharmacologically antagonizing 
WNK1/HSN2 normalized pathological GABA depolarization of injured spinal cord lamina II 
neurons. These data provide mechanistic insight into, and a compelling therapeutic target for, 
neuropathic pain after nerve injury.  
Introduction 
Chronic neuropathic pain after peripheral nerve injury is common, debilitating, often 
resistant to treatment, and an economic burden on society (1). Novel therapeutic strategies and 
druggable targets based on disease pathogenesis are needed. One contributor to neuropathic pain 
after nerve injury is the central disinhibition of GABAA receptor-dependent spinal nociceptive 
pathways (2) that can result from loss of function of the K+-Cl- cotransporter KCC2 (encoded by 
SLC12A5), which leads to Cl– accumulation in dorsal horn (DH) postsynaptic neurons (3). A 
compelling potential analgesic strategy is to restore ionotropic GABAergic inhibition by 
enhancing KCC2 activity in DH neurons (4). However, the specific mechanisms responsible for 
the injury-induced impairment of KCC2-dependent Cl– extrusion are poorly understood, and 
pharmacologic KCC2 activators are only beginning to be discovered (4).  
The study of rare monogenic diseases can identify key regulatory genes in complex 
pathways, and these genes may also be relevant to more common forms of diseases with similar 
symptoms. Hereditary sensory and autonomic neuropathy type IIA (HSANII; OMIM #201300) 
is an autosomal recessive ulcero-mutilating neuropathy characterized by the progressive 
reduction of pain, temperature, and touch sensation, and neurodegeneration in DH and dorsal 
root ganglia (DRG) neurons of the spinal cord and neurodegeneration of peripheral nerves (5). 
PRKWNK1, encoding the kinase WNK1, is alternatively spliced with one isoform containing a 
nervous system-specific exon called HSN2 (6).  Mutations in the HSN2 exon cause HSANII (6). 
Intronic deletions in PRKWNK1, which cause overexpression of a WNK1 isoform lacking the 
HSN2-specific exon in the kidney, result in pseudohypoaldosteronism type 2C (PHA2C; OMIM 
#614492) (7), an autosomal dominant form of Cl--sensitive hypertension resulting from WNK1-
dependent constitutive phosphorylation and activation of the Na+, Cl- cotransporter NCC, a 
renal-specific cation-Cl- cotransporter (CCC) related to KCC2 (8).  
The HSN2 variant of WNK1 (referred to hereafter as WNK1/HSN2) is highly expressed 
in the DH, DRG, and peripheral nerves (9), but the normal function, downstream targets, and 
pathogenic mechanism by which mutations in WNK1/HSN2 cause disease are unknown. 
WNK1-dependent inhibitory phosphorylation of KCC2 maintains the depolarizing action of 
GABA in the developing mouse brain (10). In immature neurons, WNK1 inhibition triggers a 
hyperpolarizing shift in GABA activity by reducing KCC2 Thr906 and Thr1007 phosphorylation 
and enhancing KCC2-mediated Cl– extrusion. However, whether WNK1/HSN2 regulates KCC2 
in the spinal cord is unknown. To begin to elucidate the role of WNK1/HSN2 in vivo, we 
generated a Wnk1/Hsn2-knockout mouse and investigated the development of neuropathic pain 
in the spared nerve injury (SNI) pain model and the complete Freund’s adjuvant (CFA) model of 
inflammatory pain. 
Results 
Wnk1∆Hsn2/∆Hsn2 mice have normal spinal and sensory nerve morphology and no gross 
neurological deficits 
We utilized Cre recombinase technology to generate a knockout mouse model of the 
Wnk1/Hsn2 isoform by specifically targeting the Hsn2 exon (Figure 1A). Homozygous animals 
with the Wnk1/Hsn2-floxed allele (Wnk1flox/flox) were crossed to the pCX-NLS-Cre general 
deletor strain, and the resulting heterozygote animals (Wnk1∆Hsn2/+) were crossed together to 
generate both mutant (Wnk1∆Hsn2/∆Hsn2) and wild-type (Wnk1+/+) animals. This resulted in specific 
depletion of the Wnk1/Hsn2 isoform, as revealed by the lack of Wnk1/Hsn2 transcripts in 
Wnk1∆Hsn2/∆Hsn2 but not Wnk1+/+ mice (Fig. 1B). The HSN2 form of WNK1 can be detected by 
Western blotting with an isoform-specific antibody, which showed that HSN2 was lacking from 
knockout mouse cerebrum, cerebellum, spinal cord, and liver (Fig. 1B). Wnk1∆Hsn2/∆Hsn2 mice 
exhibited no gross anatomical abnormalities, including ulcerative mutilations in either upper or 
lower limbs, after up to 80 weeks of observation. Histological examination of small and large 
nerve fibers in lumbar (L4) dorsal and ventral spinal roots and of sural sensory nerves revealed 
normal axonal distribution and morphology in Wnk1∆Hsn2/∆Hsn2 mice (Fig. 1C and Table 1 and 
Fig S1).  
Wnk1∆Hsn2/∆Hsn2 mice performed similarly to Wnk1+/+ mice in the SHIRPA protocol, a 
standardized, 3-stage battery of tests of general behavioral and neurological function (11), the 
elevated plus maze and light dark box test (assessing fear of new places and anxiety), and the 
hole board test (assessing spontaneous motor activity and exploration) (Table 2). To monitor 
nociceptive responses, we measured sensitivity to hot and cold using multiple assays, tactile 
sensitivity to pressure, and sensitivity to chemical irritants or inflammatory stimuli. 
Wnk1∆Hsn2/∆Hsn2 male mice exhibited a significantly increased latency to tail withdrawal at both 
47°C and 49°C  (Fig. 1D), but otherwise Wnk1∆Hsn2/∆Hsn2 mice exhibited similar response 
thresholds compared to Wnk1+/+ mice in tests assessing noxious thermal and mechanical 
sensitivity (Table 2). Global deletion of Wnk1/Hsn2 in mice, therefore, did not phenocopy the 
sensory neuropathy seen in HSANII patients, which is due to truncating mutations that leave the 
N-terminal kinase domain  intact (6). Indeed, Wnk1/Hsn2 knockout produced no significant 
neurological effects in these assays other of a mild, male-specific reduction in distal thermal 
sensitivity. 
Wnk1/Hsn2-knockout reduces pain hypersensitivity associated with nerve injury 
Given the HSANII phenotype and localization of WNK1/HSN2 (6, 9), we hypothesized 
that WNK1/HSN2 had a role in chronic pain hypersensitivity after nerve injury or in response to 
inflammation. We compared the neurobehavioral responses of Wnk1∆Hsn2/∆Hsn2 and Wnk1+/+ mice 
in two different pain models. We used the spared nerve injury (SNI) model of chronic 
neuropathic pain by ligating the tibial and common peroneal nerves (12), and the Complete 
Freund’s Adjuvant (CFA) model of inflammatory pain by injecting CFA into the hind paw to 
trigger inflammation. To assess sensitivity to cold, we measured the duration of hind paw 
flicking in response to the sensation induced by the application and evaporation of acetone to the 
foot pad; to assess the sensitivity to heat, we measured the time to move the paw away from a 
high energy beam of light (the Hargreaves assay); and to assess sensitivity to mechanical stimuli, 
we used the von Frey assay of poking the paw with a filament and recording the force required to 
elicit a withdrawal response.  Because SNI animals do not show heat allodynia (12), we 
compared the sensitivity to cold in the SNI pain model, sensitivity to heat in the CFA pain 
model, and mechanical allodynia in both models. In the SNI pain model, Wnk1∆Hsn2/∆Hsn2 mice at 
both early and delayed time points (up to 21 days) exhibited significantly attenuated responses to 
the evaporation of acetone and pressure measured with von Frey filaments, indicating decreased 
cold hyperalgesia and mechanical allodynia, respectively (Fig. 1D). In contrast, in the CFA pain 
model, Wnk1∆Hsn2/∆Hsn2 mice performed similarly to Wnk1+/+ mice in tests measuring mechanical 
(von Frey) and thermal (Hargreaves) nociception (Table 3). Therefore, Wnk1/Hsn2 knockout 
reduced pain hypersensitivity associated with nerve injury but not hypersensitivity resulting from 
inflammation. 
Knockout of Wnk/Hsn2 prevents SNI-induced inhibitory phosphorylation of KCC2 
The WNK family of kinases stimulate the downstream SPS1-related proline/alanine-rich 
kinase (SPAK) or the SPAK analogue, oxidative stress responsive kinase-1 (OSR1), to regulate 
the CCCs (13), stimulating the Na+, K+, Cl- cotransporter NKCC1 and inhibiting KCC2, through 
phosphorylation at multiple residues in a homologous motif in each transporter 
(NKCC1Thr202/Thr207/Thr212; KCC2Thr906/Thr1007) (14, 15). Dephosphorylation of KCC2 at these sites 
significantly stimulates KCC2 activity (14, 15), such that activation of the GABAA Cl--
conducting channel elicits hyperpolarization even in neurons with extremely negative resting 
membrane potentials (16). To determine if lack of WNK1-dependent phosphorylation of CCCs 
contributed to the decreased pain hypersensitivity in the Wnk1∆Hsn2/∆Hsn2 mice, we examined the 
phosphorylation status of NKCC1Thr202/Thr207/Thr212 and KCC2Thr906/Thr1007 in spinal cords from 
naïve and SNI-subjected mice (Fig. 2A and 2B). We observed a low amount of phosphorylation 
of KCC2 at Thr906 and a higher amount of phosphorylation at Thr1007 in the Wnk1+/+ animals 
under control conditions, and the phosphorylation at these two sites in the naïve Wnk1∆Hsn2/∆Hsn2 
mice was significantly less than that of the naïve Wnk1+/+ mice (P < 0.001). SNI significantly 
increased phosphorylation at both sites in KCC2 in mice of both genotypes; however, the 
increase in the phosphorylation status in the Wnk1∆Hsn2/∆Hsn2 mice resulted in an amount of 
phosphorylation that was similar to those seen in naïve Wnk1+/+ mice.  
Interestingly, in the Wnk1+/+ mice the amount of WNK1/HSN2 was also increased by 
SNI. In contrast, phosphorylation of NKCC1Thr202/Thr207/Thr212 and the abundance of SPAK and 
OSR1 were unchanged by WNK1/HSN2 knockout in either naïve mice or after SNI (Fig. 2A 
and 2B). We did not detect differences under any condition in the phosphorylation of SPAK at 
Ser373, a WNK phosphorylation target in the non-catalyitic C-terminal domain with an unclear 
role in SPAK regulation (17), indicating that the degree of SPAK Ser373 phosphorylation is 
independent of WNK1/HSN2 abundance. We quantified the amount of the kinase ERK1 as a 
negative control, because this kinase has not been implicated as a regulator of KCC2 or as a 
component of the WNK pathway.  
Genetic knockout or pharmacologic inhibition of Wnk1/Hsn2 restores SNI-induced GABA-
mediated depolarization in lamina II neurons 
Impaired KCC2-dependent Cl– extrusion results in depolarizing GABA-evoked responses 
in rat spinal nociceptive pathways after SNI (3, 4). We performed electrophysiology of lamina II 
neurons in spinal cord slices derived from naïve mice, sham-operated controls, or those subjected 
to the SNI pain model in the presence of vehicle or STOCK1S-50699 (18), a specific inhibitor of 
WNK signaling that activates the KCCs by reducing KCC inhibitory phosphorylation (15) (Fig. 
2C-2E). To detect the activity of KCC2, we delivered Cl- through the patch pipette and measured 
the response of the neurons to GABA. If KCC2 is active, the excess Cl- is extruded and GABA 
promotes hyperpolarization; if KCC2 activity is inhibited, the intracellular Cl- remains high and 
the apparent reversal potential for the GABA-induced current (EGABA) shifts to a less negative 
value.  Thus, by measuring the apparent EGABA under these Cl- challenge conditions, we can 
indirectly monitor KCC2 activity (19). We found that EGABA in lamina II neurons from SNI mice 
was significantly less negative than in lamina II neurons from naïve mice or sham-operated 
controls. In mice subjected to SNI, EGABA was restored to more negative values by slice 
incubation with STOCK1S-50699 for 30 to 45 minutes prior to recording, reflecting an increase 
in neuronal Cl– extrusion capacity. Similarly, in lamina II neurons derived from Wnk1∆Hsn2/∆Hsn2 
mice, EGABA was not altered after SNI (Fig. 2F). STOCK1S-50699 had no significant effect on 
EGABA in naïve animals (Fig. 2E). 
Discussion 
Here, we report the generation of a Wnk1/Hsn2-knockout mouse inspired by the mutation 
in the HSN2 exon that causes HSANII. Global deletion of Wnk1/Hsn2 in mice did not produce 
the phenotype of HSANII patients. Whereas patients with HSANII exhibit a progressive 
neuropathy characterized by the progressive reduction of pain, temperature, and touch sensation, 
and neuronal degeneration (6), Wnk1∆Hsn2/∆Hsn2 mice lacked any neurological defects except for a 
mild male-specific reduced distal thermal sensitivity. The difference between these phenotypes 
may be due to the nature of HSN2 mutation in either case. The mutations that cause HSANII 
result in a truncated protein that retains the N-terminal kinase domain (6), which may produce a 
kinase lacking critical regulatory regions and with altered substrate specificity. In contrast, the 
Wnk1∆Hsn2/∆Hsn2 do not produce the nervous system-specific WNK1/HSN2 isoform, but otherwise 
produce fully functional WNK1 expressed in other tissues. Thus, this knockout model is useful 
for exploring the specific functions of this isoform without compromising other WNK1 
functions.   
Our results suggested that WNK1/HSN2 contributes to a maladaptive decrease in KCC2 
activity and loss of GABA-mediated inhibition of neuronal activity that is associated with 
chronic pain hypersensitivity after nerve injury. Furthermore, our data indicated that the 
reduction in KCC2 activity in response to nerve injury resulted from an increase in 
WNK1/HSN2-dependent inhibitory phosphorylation of KCC2 at Thr906 and Thr1007. Kinases are 
highly-druggable molecules that have been successfully targeted in cancer but have been 
infrequently targeted for neurological diseases (20). The nervous system-specific expression of 
WNK1/HSN2, its importance for human physiology as evidenced by the diseases associated with 
its mutation, and the beneficial impact of its genetic inhibition on neuropathic pain behavior 
without producing other major neurological phenotypes in mice, suggests that WNK1/HSN2 is a 
compelling therapeutic target worthy of future investigation. 
Materials and Methods 
Generation of floxed Hsn2 and knockout mice 
The Hsn2-containing genomic regions and its neighbouring exons (8b, 11) were obtained 
by PCR amplification of three separate fragments from total genomic DNA of 129S1/SvImJ 
origin (table S2). The three separate fragments were assembled using the SLIC method, and 
cloned in a modified pDELBOY-3X vector (Addgene plasmid 13440) (21-24). The construct 
included a 5’ and 3’ homology arms, allowing homologous recombination within the Wnk1 gene, 
as well as the Hsn2 exon flanked with two loxP sites. The construct also contained a 
phosphoglycerate kinase (PGK) promoter-driven neomycin resistance cassette flanked by two frt 
sites within the 5’ homology arm that was used as a positive selection marker, and a PGK-driven 
diphtheria gene used as a negative selection marker that lay downstream of the 3’ homology arm 
(fig. 1A). All construct and DNA fragments were sequenced verified at each step and checked 
for correct orientation prior to electroporation in embryonic stem cells (ESCs). 
The targeting vector was electroporated in R1 (+Kitl-SlJ) ESCs using a Gene Pulser Xcell 
electroporator (BioRad, Mississauga, Canada). Briefly, 25 µg of vector DNA were linearized 
using the unique NotI restriction site and electroporated in 10 to 20 X 106 ESCs with the 
following conditions: ionic strength, low; pulse length, 960 µF; voltage, 250 V at room 
temperature. The cells were grown in double selection media and proper recombinant clones 
were first verified by PCR screening (table S1). Clones passing this first screening process were 
further confirmed by Southern blot analyses (fig. S2). Using this procedure, one correctly 
targeted ESC clone was recovered from 300 candidates. The correctly targeted clone was 
microinjected into C57BL/6J mouse blastocysts from which eight resulting male chimeras from 
the same clone were obtained that showed germline transmission. Three resulting strains (351, 
352, 355) were backcrossed for two to three generations to mice on the C57BL/6J-background 
(N2-3) and kept for histological and nociception characterization. 
Mice were screened for carrying a loxP-flanked Hsn2 allele using PCR genotyping (see 
table S1 for primers). The Hsn2 exon was removed by crossing homozygote animals harboring 
the Wnk1/Hsn2-floxed allele (Wnk1flox/flox) to animals expressing the Cre recombinase under the 
activity of the chicken β-actin gene (general-deletor, pCX-NLS-Cre animals). The resulting 
animals contained an intact allele of the Hsn2 exon and a recombined allele (Wnk1∆Hsn2/+). The 
cre recombinase transgene was outbred and experimental animals were generated by subsequent 
mating of two heterozygotes animals for the Hsn2 recombined allele (X/Y, Wnk1∆Hsn2/+; X/X, 
Wnk1∆Hsn2/+) that yielded both knockout (Wnk1∆Hsn2/∆Hsn2) and wild-type animals (Wnk1+/+). All 
mice were maintained on a standard light cycle of 12 hours on and 12 hours off and had food and 
water ad libitum. This study was conducted in compliance with the ethic committees at the 
Centre Hospitalier de l’Université de Montréal, the McGill University, and was approved by the 
Boston Children's Hospital Animal Care and Use Committee. All experiments were performed in 
a blinded fashion in a quiet room (temperature 22±1°C) from 9 AM to 6 PM. 
RNA extractions and RT-PCR 
RNA extractions from different neuronal and non-neuronal tissues (brain, cerebellum, 
spinal cord, liver, kidney) of Wnk1∆Hsn2/∆Hsn2 and Wnk1+/+ animals were performed using 
TRIzol® Reagent (Invitrogen by Life technologies, Cat. No.15596-018). Reverse transcription 
was performed with 1 μg of total RNA per reaction mix using SuperScriptTM III Reverse 
Transcriptase (18080-044) (Invitrogen). PCR was performed with 5 μl of first-strand cDNA 
using primers pairs listed in table S1 and Taq DNA Polymerase (Qiagen). A thermocycler was 
used with the following parameters: a nucleic acid denaturation/reverse transcriptase inactivation 
step (94°C, 4 min) followed by 35 cycles of denaturation (94°C, 1 min) and annealing (55°C, 40 
sec) and primer extension (72°C, 50 sec) followed by final extension incubation (72°C, 10 min). 
For each amplification, an internal control (RNA polymerase) was co-amplified. 
Tissue preparation and histological analyses 
Mice from the strain 352, between 10 and 13 months of age were anaesthetized with 
ketamine (100 mg/ml) and xylazine (20 mg/ml) prior to perfusion with saline solution and 3% 
glutaraldehyde. The dorsal and ventral spinal roots (n=3-4 mice per group) from the lumbar 4 
(L4) spinal section, as well as sural nerves (n=5-6 mice per group) were dissected and post-fixed 
overnight. After several washes, the tissues were osmicated with 2% osmium tetroxide 
(Canemco), dehydrated, and embedded with Epon [TAAB 812 resin (45%), Distilled Dodecenyl 
Succinic Anhydride (DDSA) (35%), nadic methyl anhydride (18%), Tri-(dimethylaminomethyl) 
phenol (DMP30) (2%)] (Canemco). The tissues were cut (5 µm thick) and mounted on glass 
slides. Sections were stained with toluidine blue and observed under light microscopy. The 
number of axons was counted and classified into 1 µm groups for each type of nerves. Axon 
diameters were calculated at magnification 320 X from surface areas using the particle analysis 
function in Image J (http://imagej.nih.gov/ij/). The total numbers of axons for each type of 
nerves were counted, averaging 600, 530, and 2,100 axons for dorsal roots, ventral roots, and 
sural nerves, respectively. 
General behavior phenotyping tests 
 SHIRPA 
The SHIRPA test was performed according to the method described by Rogers et al. 
(1997) (11). Briefly, SHIRPA is a 3-stage protocol designed to identify neurologic and 
behavioral phenotypic abnormalities in mice. The first stage provides a general behavioral 
observation profile, during which the tester observes undisturbed mice for any abnormal 
behaviors or movements. The second stage includes a host of behavioral tests that generate 
quantitative phenotypic data, including tests of locomotor activity, food and water intake, 
balance and coordination, and analgesia, along with histological and biochemical analysis of 
tissues sampled from test mice. Finally, the third stage adds more detailed testing based on 
known or potential modes of neurologic disease, including tests of anxiety, learning and 
memory, prepulse inhibition, and others.  
 Elevated plus maze 
The elevated plus maze (Noldus, NL) was constructed of black plastic with 2 “open” 
arms with no walls and 2 “closed” arms with walls (30 × 5 cm) extending out opposite from each 
other from a central platform (decision zone) to create a “plus” shape. The arms were raised 85 
cm above the floor. At the start of a trial, a mouse was placed on the center platform of the maze, 
facing a closed arm, and allowed to explore the apparatus for 5 minutes. The maze was cleaned 
between subjects with a weak ethanol solution. A computer-assisted video-tracking system 
(Ethovision XT 9.0, Noldus, NL) recorded the total time spent exploring the different regions of 
the maze [open arms, center (decision zone) and closed arms]. The percent time spent in open 
arms (defined as when all 4 paws were placed on the open arm) was used as a surrogate measure 
of exploratory behavior in a novel environment; mice with lower amounts of open arm 
exploratory activity have greater neophobia (fear of new stimuli). 
Light-dark box 
The light and dark box was a plastic box divided into two compartments and connected 
by an aperture in the divider separating the two compartments. One compartment was 
constructed of white plastic and was 66% of the box and the other compartment was made of 
black plastic and formed 33% of the box. There was also a lid on top of the black compartment. 
A computer-assisted video-tracking system (Ethovision XT 9.0, Noldus, NL) recorded the total 
time spent exploring the different regions of the box. The percent time spent in the white side of 
the box (defined as when all 4 paws were placed in the white side of the box) was used as a 
surrogate measure of exploratory behavior in a novel environment; mice with lower amounts of 
white side exploratory activity have greater neophobia. 
 Hole board 
The hole-board test was used to assess mouse exploratory behavior in a novel 
environment. The apparatus was an acrylic box with a floor and 4 walls (40 cm × 40 cm × 30 
cm). The plastic floor contained 9 holes evenly spaced apart that were 2 cm deep. Mice were 
placed in the box for 15 minutes. Gross (for example, walking and running) and fine (for 
example, active grooming but not moving from one position) motor activity pertaining to 
location in the box and proximity to the 9 holes was recorded through interruption of infrared 
beams located in the walls of the arena (for horizontal activity and fine movements) and in the 
holes to measure exploratory head dips.  
Nociception tests 
All behavioral experiments were performed with handlers blinded to groups. 
Wnk1∆Hsn2/∆Hsn2 and Wnk1+/+ mice from three different strains backcrossed onto the C57BL/6J-
background were used for nociception analyses (strain 351, 352, 355) in two different centers 
(McGill and Boston Children’s Hospital). The animals were tested simultaneously over the same 
day, tested in multiple litters, and assessed in the same cohort of animal (n=7-10 per genotype for 
each group). All mice were acclimated to their novel environment for 3 months prior to study. 
All mice were 5–11 months old when the study began with the exception of mice undergoing 
SNI, which was performed at 3 months. All nociceptive assays executed in this study have been 
fully described in detail in the literature (25-29). Tests measuring mechanical (von Frey) and 
thermal (Hargreave’s) nociception stimuli were utilized in the CFA model of inflammatory pain 
as described (30). For neuropathic pain, mechanical allodynia (von Frey filaments test) (31) and 
cold hypersensitivity [evaporation of a drop of acetone (32)] were assessed before and up to 21 
days after peripheral nerve injury (SNI).  
Surgeries 
SNI surgery was performed under 3% induction/2% maintenance with isoflurane on adult 
mice. The tibial and common peroneal branches of the sciatic nerve were tightly ligated with a 
5.0 silk suture and transected distally, while the sural nerve was left intact as previously 
described (12). After injury, the incision was sutured and mice were allowed to recover on 
heated pads before being returned to their home cages. 
Statistical analyses 
Statistical data were analyzed using STATISTICA© 10 (StatSoft, Inc., Tulsa, OK, USA) 
and SPSS. Data were initially examined using Shapiro-Wilk test for normal distribution. Data 
that did not fit a normal distribution underwent non-parametric analysis, whereas data that were 
normally distributed were subjected to parametric analysis. Axon diameter, Hargreaves plantar, 
hotplate Hargreaves, hot plate, von Frey, and formalin data were not normally distributed and, 
therefore, underwent non-parametric analyses (Kruskall-Wallis ANOVA). Tail-clip data and tail-
withdrawal data were analyzed using factorial ANOVA for genotype and sex effects. All chronic 
tests (SNI mechanical sensitivity, CFA mechanical and thermal sensitivity) were analyzed using 
mix model ANOVA. Post hoc tests with Bonferroni correction were performed for between and 
within-subject comparisons when appropriate. All data are reported as mean values ± standard 
error of the mean (SEM). 
Buffers 
Buffer A contained 50 mM Tris/HCl, pH7.5 and 0.1mM EGTA. Lysis buffer was 50 mM 
Tris/HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 50 mM sodium fluoride, 5 mM sodium 
pyrophosphate, 1 mM sodium orthovanadate, 1% (w/v) Triton-100, 0.27 M sucrose, 0.1% (v/v) 
2-mercaptoethanol and protease inhibitors (complete protease inhibitor cocktail tablets, Roche, 1 
tablet per 50 mL). TBS-Tween buffer (TTBS) was Tris/HCl, pH 7.5, 0.15 M NaCl and 0.2% 
(v/v) Tween-20. SDS sample buffer was 1X NuPAGE LDS sample buffer (Invitrogen), 
containing 1% (v/v) 2-mercaptoethanol. 
Antibodies 
Antibodies used for Western Blots included antibodies raised in sheep and affinity-
purified on the appropriate antigen by the Division of Signal Transduction Therapy Unit at the 
University of Dundee: KCC2a total antibody [residues 1-119 of human KCC2a]; KCC3a 
phospho-Thr991 [residues 975-989 of human KCC3a phosphorylated at Thr991, 
SAYTYER(T)LMMEQRSRR, corresponding to residues of rat KCC2 phosphorylated at Thr906, 
SAYTYEK(T)LMMEQRSRR]; KCC2a phospho-Thr906 [residues 975-989 of human KCC3a 
phosphorylated at Thr991, SAYTYER(T)LMMEQRSRR]; KCC3a phospho-Thr1039/1048 [residues 
1032-1046 or 1041-1055 of human KCC3a phosphorylated at Thr 1039/1048, 
CYQEKVHM(T)WTKDKYM, corresponding to residues of rat KCC2 phosphorylated at 
Thr1006, TDPEKVHLTW(T)KDKSV]. NKCC1 total antibody [residues 1-288 of human 
NKCC1]; NKCC1 phospho-Thr203/Thr207/Thr212 antibody [residues 198-217 of human NKCC1 
phosphorylated at Thr203, Thr207 and Thr212, HYYYD(T)HTN(T)YYLR(T)FGHNT]; SPAK total 
antibody [full-length GST-tagged human SPAK protein]; SPAK/OSR1 (S-motif) phospho-
Ser373/Ser325 antibody [367–379 of human SPAK, RRVPGS(S)GHLHKT, which is similar to 
residues 319–331 of human OSR1 in which the sequence is RRVPGS(S)GRLHKT); HSN2 total 
antibody [full-length human WNK1/HSN2 protein]; ERK1 total antibody [full-length human 
ERK1 protein]. KCC2 total antibody [residues 932-1043 of rat KCC2] was purchased from 
NeuroMab. Secondary antibodies coupled to horseradish peroxidase used for immunoblotting 
were obtained from Pierce. IgG used in control immunoprecipitation experiments was affinity-
purified from pre-immune serum using Protein G-Sepharose. 
Phosphorylation-specific antibody immunoprecipitations 
KCCs phosphorylated at the KCC2 Thr906 and Thr1007 equivalent residue were 
immunoprecipitated from clarified spinal cord lysates. The phosphorylation-specific antibody 
was coupled to protein-G–Sepharose at a ratio of 1 mg of antibody per 1 mL of beads. A total of 
2 mg of clarified spinal cord lysate were incubated with 15 µg of antibody conjugated to 15 µL 
of protein-G–Sepharose in the presence of 20 µg/mL of the corresponding dephosphorylated 
peptide dissolved in buffer. Incubation was carried for 2 hours at 4°C with gentle agitation, and 
the immunoprecipitates were washed three times with 1 mL of lysis buffer containing 0.15 M 
NaCl and twice with 1 mL of buffer A. Bound proteins were eluted with 1X lithium dodecyl 
sulfate (LDS) sample buffer.  
Immunoblotting 
Spinal cord lysates (15 µg) in SDS sample buffer were subjected to electrophoresis on 
polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were 
incubated for 30 min with Tris-buffered salt solution with Tween (TTBS) containing 5% (w/v) 
skimmed milk. The membranes were then immunoblotted in 5% (w/v) skimmed milk in TTBS 
with the indicated primary antibodies overnight at 4°C. Sheep antibodies were used at a 
concentration of 1-2 µg/ml. The incubation with phosphorylation-specific sheep antibodies was 
performed with the addition of 10 µg/mL of the dephosphorylated peptide antigen used to raise 
the antibody. The blots were then washed six times with TTBS and incubated for 1 hour at room 
temperature with secondary HRP-conjugated antibodies diluted 5000-fold in 5% (w/v) skimmed 
milk in TTBS. After repeating the washing steps, the signal was detected with the enhanced 
chemiluminescence reagent. Immunoblots were developed using a film automatic processor 
(SRX-101; Konica Minolta Medical) and films were scanned with a 600-dpi resolution on a 
scanner (PowerLook 1000; UMAX). Figures were generated using Photoshop/Illustrator 
(Adobe). 
Electrophysiological recordings in spinal neurons 
All electrophysiology experimental procedures were conducted in conformity with the 
recommendations of the European Union directive on animal experimentation (2012/63/EU). 
Whole-cell patch-clamp recordings were performed in 300 μm transverse slices of lumbar 
segment L4 to L6 as previously described (4, 33, 34). For experiments involving SNI mice, all 
recordings were performed in the ipsilateral side of the nerve injury. Recordings were performed 
at room temperature in standard artificial cerebrospinal fluid (ACSF). Data were filtered at 10 
kHz and acquired using pClamp 10 (molecular device). Borosilicate patch pipettes (4-6 MΩ) 
were filled with (composition in mM): 120 K-methanesulfonate, 25 KCl, 10 HEPES, 2 MgCl2 
(pH 7.3). To measure EGABA under a Cl- challenge, neurons in lamina II were recorded while 
GABA (1 mM) was puffed locally for 30 ms. Experimental EGABA was extrapolated from GABA 
I-V curve relationship. For STOCK1S-50699 (Molport, LV) experiments, slices were incubated 
in STOCK1S-50699 (10 μM for 30-45 minutes) before recordings. 
Supplementary Materials 
Fig. S1. Nerve size quantification of the L4 ventral and dorsal spinal roots, and sural sensory 
nerves, of Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice. 
Fig. S2. Southern blot analyses revealed correctly targeted ESC clones using Wnk1-specific 5ʹ 
and 3ʹ probes. 
Table S1. PCR primers used. 
Table S2. Performance of Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice in assays testing general central 
nervous system function. 
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Fig. 1. Wnk1/Hsn2-knockout in mice results in a mild sex-dependent loss of distal thermal 
sensitivity and reduces chronic pain hypersensitivity after peripheral nerve injury. 
 (A) Recombination scheme and (B) Western blot analysis confirming that HSN2 is not detected 
from knockout mouse brain (Br), cerebellum (Cer), spinal cord (SC), and liver (Li). Genomic 
analysis was performed by RT-PCR with primers specific for between exon 8 and Hsn2. WNK1 
protein was analyzed in XXXd with an antibody that recognizes the HSN2 isoform specifically. 
(C)  Wnk1∆Hsn2/∆Hsn2 mice exhibit normal axonal distribution and morphology. (Left) Histological 
transverse sections of ventral and dorsal spinal roots of lumbar 4 (L4) as well as sural nerves of 
11 month-old Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice (scale = 10 mm). (Right) Quantification of 
nerve diameter and distribution of nerve fibers in Wnk1∆Hsn2/∆Hsn2 mice and Wnk1+/+ mice is 
shown. The Kruskal-Wallis H test was performed on 3-6 mice of each genotype. Error bars 
represent standard error of the mean. See table S1 for statistical analysis. No statistically 
signficant differences were detected. 
(D) Wnk1∆Hsn2/∆Hsn2 mice exhibit only a mild, sex-dependent loss of distal thermal sensitivity 
without other apparent neurological deficits. Latency of females and males for tail withdrawal 
from either 47°C or 49°C water. Tail-withdrawal test was performed on 8 Wnk1+/+ and 7 
Wnk1∆Hsn2/∆Hsn2 males, and 8 Wnk1+/+ and 10 Wnk1∆Hsn2/∆Hsn2 females. Error bars represent the 
mean ± SEM, **P < 0.05, *P < 0.01, Two-way ANOVA with Bonferroni post test.  
(E) Response to acetone evaporation as a measure of cold allodynia. Duration of paw flicking 
response to evaporation of acetone was tested on 7-8 mice per group (Wnk1∆Hsn2/∆Hsn2, Wnk1+/+).  
(F) Response to von Frey stimulation as a measure of mechanical hypersensitivity. Withdrawal 
threshold to von Frey hairs of varying diameters that apply a range of forces to the paw 
(measured in grams) was tested on 7-8 mice per group (Wnk1∆Hsn2/∆Hsn2, Wnk1+/+). Mixed model 
ANOVA with Bonferroni post-hoc testing was performed on test results with between factor 
variable being genotype and within factor variable being time (days). Error bars represent the 
mean ± SEM. *P < 0.01. 
Fig. 2. Antagonizing spinal Wnk1/Hsn2 kinase signaling decreases maladaptive KCC2 inhibitory 
phosphorylation and normalizes depolarizing GABA-evoked responses after nerve injury. 
(A) Spinal cord homogenates were subjected to Western blot analysis of either 
immunoprecipitates or lysates with the indicated antibodies. Proteins or phosphorylated proteins 
recognized by the antibodies that were used for immunoprecipitation are indicated with IP, 
proteins recognized by antibodies that were used for Western blotting are indicated with IB. The 
WNK1/HSN2 antibody is specific for this isoform.  The Western blots illustrate results obtained 
in two separate experiments.  
(B) Quantification of indicated Western blot data from results shown in A. The quantification 
(ratio calculation) is based on (phospho KCC2) / (total KCC2), or HSN2/ERK1. Statistical 
analysis was performed using unpaired t-test (n=3, all values represent the mean ± SEM, ***, 
p<0.001; **, p<0.01; *, p<0.05). 
(C) Representative currents recorded in spinal cord lamina II neurons from naive and SNI-
subjected (1 week) adult mice in response to 30 ms puffs of GABA (1 mM) in the presence of a 
Cl- load (29 mM), introduced through the patch pipette. Slices were incubated for 30 to 45 
minutes with vehicle control or STOCK 1S-50699 (10 μM) prior to recording. 
(D) Current-voltage (IV) relationship for GABA normalized currents (I/-I80mV) obtained from 
naïve mice under control conditions (n=13) or after SNI treatment (1 week), in the presence of 
vehicle control (n=9) or STOCK1S-50699 (n=14). Conditions as described in C. 
(E) Apparent EGABA measured in lamina II spinal cord neurons from naïve mice under control 
conditions (n=13) or after treatment with STOCK1S-50699 (n=6). Also shown are EGABA 
measurements in sham-operated mice (1 week) under control conditions (n=6) or after treatment 
with STOCK1S-50699 (n=5), and in SNI (1 week) under control conditions (n=9) or after 
STOCK1S-50699 treatment (n=14). Data are presented as mean ± S.E.M. Two-way analysis of 
variance (ANOVA), with factors surgery and treatment (Bonferroni **P < 0.05, *P < 0.01). XX 
(F) Apparent EGABA measured in lamina II neurons from Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice under 
control or SNI (1 week) conditions. Data are presented as mean ± S.E.M. Unpaired t-test; **P < 
0.05. 
(G) Statistical analysis of the differences in KCC2 phosphorylation between Wnk1+/+ and 
Wnk1∆Hsn2/∆Hsn2 under control and SNI conditions and of differences in apparent EGABA between 
Wnk1+/+ mice under control, sham-operated, and SNI conditions in the presence and absence of 
STOCK1S-50699.   
Table 1. Nerve size quantification summary of Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice. Statistical 
results associated with the nerve size calculation from both Wnk1∆Hsn2/∆Hsn2 and Wnk1+/+ animals 
are presented. Column one to three present results from the ventral L4, dorsal L4, and sural nerve 
with their respective P-values.  
 
Table 2. Performance of Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice in assays testing general central 
nervous system function. Four of each genotype were assessed in each test. 
Test Metric P-values 
SHIRPA Combined score 0.5039 
Elevated plus maze  % time on open arms 0.8394 
Total distance traveled 0.4002 
Light and dark box Time in light side 0.064 
Holeboard Total distance traveled  0.4236 
Holes poked in center 0.5414 
Holes poked in periphery 0.5021 
 
Table 3. Nociception test summary for Wnk1+/+ and Wnk1∆Hsn2/∆Hsn2 mice. Statistical results 
from seven nociception tests performed on Wnk1∆Hsn2/∆Hsn2 and Wnk1+/+ animals are presented. 
CFA nociception tests were performed XX after CFA injection into the hind paw.  Differences at 
day 21 after SNI in nociception tests are shown. NS, nonsignificant 
 
Pain model Nociception Test P-values 
none 
Tail clip 
sex and genotype; F (1, 18) = 0.45 P = 0.51 
sex; F (1, 18) = 1.49, P = 0.24 
genotype; F (1, 18) = 0.65, P = 0.43 
none 
Hargreave 
15% female (P = 0.06) 
15% male (P =  0.73) 
20% female (P = 0.31) 
20% male (P = 0.73) 
none 
Hotplate 
50°C female (P = 0.86) 
50°C male (P = 0.35) 
53°C female (P = 0.20) 
53°C male (P = 0.56) 
none 
von Frey 
female (P = 0.71) 
male (P = 0.36) 
none 
Formalin 
early female (P = 0.82) 
early male (P = 1.00) 
late female (P = 0.82) 
late male (P = 0.32) 
CFA 
von Frey 
sex and genotype; F (7, 10) = 1.39 P = 0.33 
sex; F (7, 10) = 1.76, P = 0.23 
genotype; F (7, 10) = 1.23, P = 0.41 
CFA 
Hargreave 
sex and genotype; F (7, 10) = 1.68 P = 0.25 
sex; F (7, 10) = 1.15, P = 0.44 
genotype; F (7, 10) = 1.43, P = 0.33 
SNI acetone 
 
SNI Von Frey  
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